The FDA has approved Pyzchiva® (ustekinumab-ttwe), a biosimilar antagonist of human interleukin (IL)-12 and IL-23, for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, set to be launched in the US market by February 2025.
An economic study reveals wide-ranging costs in bringing new drugs to market, with pharmaceutical companies experiencing stable research and development (R&D) intensity, suggesting potential for reduced prices without compromising innovation.
A recent study published in JAMA Dermatology suggests that older age, higher BMI, and smoking status may be associated with reduced effectiveness of biologic treatments in psoriasis patients.
A recent study reveals that surgeons are most frequently reported for unprofessional behavior by coworkers, while pediatric-focused physicians are least likely to be reported.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Researchers found that a 12-week lifestyle modification program combining diet and exercise improved erectile dysfunction, metabolic syndrome, and psoriasis severity in men with obesity.
A study in JAMA Network Open shows a rise in influenza vaccination mandates for U.S. health care personnel, with VA hospitals increasing from 4% in 2017 to 96% in 2021.